Blood cancers

Are we there yet? The long road to cure in relapsed multiple myeloma

Sponsored by Celgene Pty Ltd

Multiple myeloma is a heterogenous disease with variability in the presentation of its cytogenetic, molecular and proliferative features. But the treatment of multiple myeloma, particularly in relapsed disease is even more complex. With a therapeutic landscape that has recently exploded with new agents and label extensions and no one standard treatment, clinicians and patients continue ...

Already a member?

Login to keep reading.

© 2021 the limbic